Visual Analysis of Research on Lung Cancer Immunotherapy by Using CiteSpace
10.3971/j.issn.1000-8578.2023.22.0495
- VernacularTitle:基于CiteSpace的肺癌免疫治疗研究的可视化分析
- Author:
Shuyan YANG
1
;
Jinman ZHUANG
;
Yuhang LIU
;
Jinxiu ZHU
;
Mengxin LIN
;
Fei HE
Author Information
1. Department of Epidemiology and Biostatistics, School of Public Health, Fujian Medical University, Fuzhou 350122, China
- Publication Type:Research Article
- Keywords:
Lung cancer;
Immunotherapy;
Single cell sequencing;
Visual analysis;
CiteSpace
- From:
Cancer Research on Prevention and Treatment
2023;50(1):43-51
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the current status of research on lung cancer immunotherapy to provide a reference for further investigation and future topic selection in this field. Methods CiteSpace visualization analysis software was used to analyze 400 Chinese studies in CNKI and 5 001 English studies in the Web of Science database from 2005 to 2021, with "lung cancer" and "immunotherapy" as keywords. Keyword co-occurrence analysis was performed on 17 English studies of "Lung Cancer" "Immunotherapy" and "Single cell sequencing" in the Web of Science database. Results "Non-small cell lung cancer" "immunosuppressants" "PD-L1" "dendritic cells" and "cytokine-induced killer cells" are current research hotspots in lung cancer immunotherapy. Monoclonal antibody drugs including nivolumab, pembrolizumab, atezolizumab, and durvalumab are hotspot drugs. Immunotherapy combined with chemotherapy as well as PD-L1 expression have become the focus of continuous research. The majority of studies on lung cancer immunotherapy are conducted in the United States, followed by China. Conclusion Lung cancer immunotherapy has gradually become a research hot spot in China. In the future, in-depth research is needed to provide cutting-edge directions for lung cancer immunotherapy.
